雷替曲塞联合经肝动脉化疗栓塞术治疗晚期大肠癌肝转移的效果观察

王保信; 张锐; 胡新华; 齐秀恒; 肖芳芳; 邢宏建; 邹庆华; 郭茜; 武振明

doi:10.3969/j.issn.1001-5256.2016.04.028

雷替曲塞联合经肝动脉化疗栓塞术治疗晚期大肠癌肝转移的效果观察

DOI: 10.3969/j.issn.1001-5256.2016.04.028

1. 中国石油天然气集团公司中心医院肿瘤科
2. 显德旺矿职工医院

基金项目:

廊坊市科学技术研究与发展计划项目(2014013021)；

详细信息

中图分类号: R735.34
计量
- 文章访问数: 2369
- HTML全文浏览量: 30
- PDF下载量: 535
- 被引次数: 0
出版历程
- 出版日期: 2016-04-20

Efficacy of raltitrexed combined with transcatheter arterial chemoembolization in treatment of advanced colorectal cancer with liver metastasis

Department of Oncology, Central Hospital of China National Petroleum Corporation

Research funding:

摘要

摘要:
目的评价雷替曲塞联合经肝动脉化疗栓塞术在治疗晚期大肠癌肝转移中的疗效。方法选取中国石油天然气集团公司中心医院2012年1月-2015年6月收治的大肠癌术后晚期肝转移的患者80例,将其随机分为研究组和对照组,每组40例。研究组给予雷替曲塞介入下肝动脉灌注化疗联合栓塞治疗,对照组给予静脉输注雷替曲塞单药治疗。以上治疗每4周1次,共进行36个周期。观察2组的治疗有效率（RR）、疾病控制率（DCR）、中位疾病进展时间、生存率以及癌胚抗原（CEA）、糖链抗原（CA）19-9、转氨酶、胆红素的下降情况。计数资料组间比较采用χ2检验,生存分析采用Kaplom-Meier法。结果研究组的RR与对照组（45.0%vs 22.5%）比较,差异有统计学意义（χ2=4.528,P=0.033）;研究组的DCR与对照组（70.0%vs 47.5%）比较,差异有统计学意义（χ2=4.178,P=0.041）。研究组的中位疾病进展时间与对照组（17.9个月vs 10.5个月）比较,差异有统计学意义（χ
- 肠肿瘤 /
- 肝肿瘤 /
- 化学栓塞,治疗性
Abstract:
Objective To investigate the efficacy of raltitrexed combined with transcatheter arterial chemoembolization( TACE) in the treatment of advanced colorectal cancer with liver metastasis. Methods A total of 80 patients with liver metastasis of advanced colorectal cancer who were admitted to Central Hospital of China National Petroleum Corporation and underwent surgery from January 2012 to June 2015 were enrolled and randomly divided into study group and control group,with 40 patients in each group. The patients in the study group underwent hepatic arterial infusion chemotherapy with raltitrexed combined with TACE,and those in the control group were treated with intravenous infusion of raltitrexed alone. The above treatment was performed once every 4 weeks for 3- 6 cycles. The response rate( RR),disease control rate( DCR),median time to disease progression,survival rate,and reductions in carcinoembryonic antigen( CEA),CA19- 9,aminotransferases,and bilirubin were observed in the two groups. The chi- square test was used for comparison of categorical data between groups.Results RR,DCR,and the median time to disease progression showed significant differences between the study group and the control group( 45. 0% vs 22. 5%,χ~2= 4. 528,P = 0. 033; 70. 0% vs 47. 5%,χ~2= 4. 178,P = 0. 041; 17. 9 months vs 10. 5 months,χ~2=24. 08,P < 0. 001). The study group had significantly higher 1- and 2- year survival rates than the control group( 80. 0% vs 57. 5%,χ~2= 4. 713,P = 0. 030; 55. 0% vs 32. 5%,χ~2= 4. 114,P = 0. 043). The study group had a significantly higher number of patients with more than 50% reductions in CA19- 9,CEA,aminotransferases,and bilirubin at 2 months after TACE than the control group( χ~2= 5. 333,4. 528,5. 051,and 5. 013,P = 0. 021,0. 033,0. 025,and 0. 025). Conclusion Raltitrexed combined with TACE is of good value in the treatment of advanced colorectal cancer with liver metastasis and holds promise for clinical application.
- intestinal neoplasms /
- liver neoplasms /
- chemoembolization,therapeutic

HTML全文

参考文献(18)

[1]YAN ZS.Adjuvant chemotherapy of colorectal carcinoma[J].Chin JGen Surg,2002,11(11):641-642.(in Chinese)宴仲舒.大肠癌辅助化疗[J].中国普通外科杂志,2002,11(11):641-642.

[2]WANG JB,WU Q,ZOU WY,et al.Therapeutic effect of raltitrexed or fluorouracil plus irinotecan as second-line treatment for advanced colorectal cancer[J].Cancer Res Prevent Treat,2014,41(12):1335-1338.(in Chinese)王俊斌,吴穷,邹维艳,等.雷替曲塞或氟尿嘧啶联合伊立替康二线治疗晚期结直肠癌疗效分析[J].肿瘤防治研究,2014,41(12):1335-1338.

[3]SHAHROKNI A,RAJEBI MR,SAIF MW.Toxicity and efficacy of5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism:a challenge or a dilemma?[J].Clin Colorectal Cancer,2009,8(4):231-234.

[4]ZHAN XX.Pharmacokinetic studies in interventional radiology[J].Foreign Med Sci:Clin Radiol,1989,6:327-329.(in Chinese)詹晓星.介入放射学中的药代动力学研究[J].国外医学临床放射学分册,1989,6:327-329.

[5]ZHU ZD,PU YD.The comparison of 5-FU pharmacokinetics after left gastric artery intraarterial infusion and by peripheral intravenous administration in treatment for gastric carcinoma[J].Chin J Gastrointestinal Surg,2000,3(1):28-30.(in Chinese)朱志东,蒲永东.氟尿嘧啶经胃左动脉和外周静脉化疗的药代动力学比较[J].中国胃肠外科杂志,2000,3(1):28-30.

[6]YAO HW,LIU YH.Interpretation of NCCN clinical practice guideline in colorectal cancer(2011 update)[J].Chin J Gastrointest Surg,2011,14(4):234-238.(in Chinese)姚宏伟,刘荫华.NCCN结直肠癌临床实践指南2011年更新解读[J].中华胃肠外科杂志,2011,14(4):234-238.

[7]WALDMAN BC,WANG Y,KILARU K,et al.Induction of intrachromosomal homologous rucombination in human cells by raltitrexed,an inhibitor of thymidylate synthase[J].DNA Repair(Amst),2008,7(10):1624-1635.

[8]WANG BX,WU ZM,ZHANG R,et al.Intervention of raltitrexed combined with epirubicin in hepatic arterial infusion and embolization in treatment of primary liver cancer[J].J Clin Hepatol,2015,31(5):725-728.(in Chinese)王保信,武振明,张锐,等.联合应用雷替曲塞及表柔比星经肝动脉化疗栓塞术治疗中晚期原发性肝癌的临床观察[J].临床肝胆病杂志,2015,31(5):725-728.

[9]YANG L.Efficacy of raltitrexed for injection in treatment of advanced colorectal cancer in elderly patients[J].China Prac Med,2014,9(26):147-148.(in Chinese)杨柳.分析注射用雷替曲塞治疗老年晚期结直肠癌的效果[J].中国实用医药,2014,9(26):147-148.

[10]KELLY C,BHUVA N,HARRISON M,et al.Use of raltitrexed as analternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history[J].Eur J Cancer,2013,49(10):2303-2310.

[11]WILSON KS,TAYLOR SCM.Raltitrexed:optimism and reality[J].Expert Opin Drug Metab Toxicol,2009,5(11):1447-1454.

[12]NISHISHO I,KIKKAWA N,EBATA T,et al.A late phase IIstudy of raltitrexed(ZD1694)in chemotherapy-naive patients with advanced colorectal cancer[J].Gan To Kagaku Ryoho,2000,27(1):81-91.

[13]ASCHELE C,BALDO C,SOBRERO AF,et al.Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro[J].Clin Cancer Res,1998,4(5):1323-1330.

[14]WANG XY,LI SG,ZHAO YF,et al.Efficacy of ralfitrexed or 5-fluorouracil combined with oxaliplatin in the treatment of advanced colorectal cancer:a meta-analysis[J].Pract J Cancer,2015,30(9):1354-1356.(in Chinese)王晓元,李曙光,赵轶锋,等.雷替曲塞或氟尿嘧啶联合奥沙利铂治疗晚期结直肠癌疗效的Meta分析[J].实用癌症杂志,2015,30(9):1354-1356.

[15]NIU N,WU R,CHEN W,et al.Clinical efficacy of raltitrexed plus oxaliplatinl in treatment of senile advanced colorectal carcinoma[J].J China Med Univ,2013,42(8):682-685.(in Chinese)牛楠,吴荣,陈威,等.雷替曲塞联合奥沙利铂治疗老年晚期结直肠癌的疗效分析[J].中国医科大学学报,2013,42(8):682-685.

[16]DONG BG,XIE GS,LI L,et al.Clinical observation of raltitrexed combined with oxaliplatin in the treatment of postoperative recurrence of advanced colorectal;cancer[J].Med Innov Chin,2014,11(2):15-16.(in Chinese)董宝国,谢桂生,李霖,等.雷替曲塞联合奥沙利铂治疗术后复发晚期大肠癌的疗效观察[J].中国医学创新,2014,11(2):15-16.

[17]ZHU DG,WANG H.The Efficacy of the combined raltitrexed plus oxaliplatin and in the treatment of senile advanced colorectal carcinoma[J].Med Innov Chin,2015,12(7):51-53.(in Chinese)朱大高,王辉.雷替曲塞联合奥沙利铂治疗晚期结直肠癌的临床疗效观察[J].中国医学创新,2015,12(7):51-53.

[18]CHEN YY.Application research of raltitrexed and oxaliplatin in treatment of elderly patients with advanced colorectal cancer[J].China Modern Med,2014,21(2):80-82.(in Chinese)陈银芸.雷替曲塞与奥沙利铂在老年晚期结直肠癌患者中的联合应用研究[J].中国当代医药,2014,21(2):80-82.

施引文献

资源附件(0)

访问统计